Finanzen von Allogene Therapeutics, Inc. (ALLO)ALLOAllogene Therapeutics, Inc.

Evaluating the bottom line, Allogene Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1011.21%, while the net margin is -919.76%. These profitability ratios, combined with a Return on Equity (ROE) of -42.39%, provide a clear picture of how effectively ALLO converts its operational activities into shareholder value.

In the context of the broader market, ALLO competes directly with industry leaders such as PROK and VALN. With a market capitalization of $452.59M, it holds a significant position in the sector. When comparing efficiency, ALLO's gross margin of 100.00% stands against PROK's 100.00% and VALN's 9.60%. Such benchmarking helps identify whether Allogene Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Allogene Therapeutics has reported zero revenue for multiple quarters, with a net loss of $42,677,000 in Q2 2026. The gross margin is 100% for Q2 2026, but this is against a backdrop of no sales, indicating a reliance on funding rather than operational income.